NeoGenomics, Inc. (NASDAQ:NEO) General Counsel Alicia C. Olivo Sells 2,669 Shares

NeoGenomics, Inc. (NASDAQ:NEO) General Counsel Alicia C. Olivo sold 2,669 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $18.39, for a total transaction of $49,082.91. Following the completion of the transaction, the general counsel now directly owns 37,140 shares in the company, valued at $683,004.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

NeoGenomics Trading Up 0.5 %

NEO traded up $0.10 during mid-day trading on Monday, hitting $19.51. The stock had a trading volume of 816,162 shares, compared to its average volume of 983,017. The stock’s fifty day simple moving average is $13.84 and its 200-day simple moving average is $15.41. The company has a debt-to-equity ratio of 0.57, a current ratio of 6.32 and a quick ratio of 6.06. The firm has a market capitalization of $2.49 billion, a price-to-earnings ratio of -25.21 and a beta of 1.23. NeoGenomics, Inc. has a 1-year low of $8.70 and a 1-year high of $20.54.

Institutional Investors Weigh In On NeoGenomics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Strs Ohio raised its holdings in shares of NeoGenomics by 9.1% during the second quarter. Strs Ohio now owns 7,200 shares of the medical research company’s stock worth $115,000 after acquiring an additional 600 shares during the period. Captrust Financial Advisors raised its holdings in shares of NeoGenomics by 17.1% during the second quarter. Captrust Financial Advisors now owns 5,780 shares of the medical research company’s stock worth $47,000 after acquiring an additional 844 shares during the period. MetLife Investment Management LLC raised its holdings in shares of NeoGenomics by 1.4% during the second quarter. MetLife Investment Management LLC now owns 67,342 shares of the medical research company’s stock worth $1,082,000 after acquiring an additional 906 shares during the period. Arizona State Retirement System raised its holdings in shares of NeoGenomics by 3.1% during the first quarter. Arizona State Retirement System now owns 34,767 shares of the medical research company’s stock worth $605,000 after acquiring an additional 1,046 shares during the period. Finally, Creative Planning raised its holdings in shares of NeoGenomics by 1.1% during the third quarter. Creative Planning now owns 102,012 shares of the medical research company’s stock worth $1,255,000 after acquiring an additional 1,080 shares during the period. 91.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. William Blair reaffirmed an “outperform” rating on shares of NeoGenomics in a research note on Monday, August 28th. Morgan Stanley raised their price objective on shares of NeoGenomics from $16.00 to $17.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $21.00 price objective on shares of NeoGenomics in a research note on Tuesday, November 7th. Piper Sandler reduced their price objective on shares of NeoGenomics from $23.00 to $18.00 and set an “overweight” rating on the stock in a research note on Monday, October 16th. Finally, The Goldman Sachs Group reduced their price objective on shares of NeoGenomics from $19.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, October 20th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $19.00.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.